WO2012047109A3 - Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death - Google Patents

Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death Download PDF

Info

Publication number
WO2012047109A3
WO2012047109A3 PCT/NL2011/050688 NL2011050688W WO2012047109A3 WO 2012047109 A3 WO2012047109 A3 WO 2012047109A3 NL 2011050688 W NL2011050688 W NL 2011050688W WO 2012047109 A3 WO2012047109 A3 WO 2012047109A3
Authority
WO
WIPO (PCT)
Prior art keywords
adenovirus
mirna
cell death
rna
modulate
Prior art date
Application number
PCT/NL2011/050688
Other languages
French (fr)
Other versions
WO2012047109A2 (en
Inventor
Victor Willem Van Beusechem
Jan Willem Hendrik Van Ginkel
Original Assignee
Orca Therapeutics B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orca Therapeutics B.V. filed Critical Orca Therapeutics B.V.
Publication of WO2012047109A2 publication Critical patent/WO2012047109A2/en
Publication of WO2012047109A3 publication Critical patent/WO2012047109A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to means and methods for identifying a mi RNA, a mi RNA mimic or a mi RNA inhibitor that modulates adenovirus replication in, and/or adenovirus induced cell death of a cell. Identified mi RNAs, mi RNA mimics or mi RNA inhibitors are used as anti-cancer agents in the context of adenovirus gene therapy.
PCT/NL2011/050688 2010-10-08 2011-10-07 Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death WO2012047109A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39113510P 2010-10-08 2010-10-08
EP10187049.1 2010-10-08
US61/391,135 2010-10-08
EP10187049 2010-10-08

Publications (2)

Publication Number Publication Date
WO2012047109A2 WO2012047109A2 (en) 2012-04-12
WO2012047109A3 true WO2012047109A3 (en) 2012-05-31

Family

ID=44168889

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2011/050688 WO2012047109A2 (en) 2010-10-08 2011-10-07 Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death

Country Status (1)

Country Link
WO (1) WO2012047109A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122385A1 (en) * 2004-04-15 2007-05-31 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Replication competent viruses capable of silencing virus inhibitory factor expression
WO2009130479A2 (en) * 2008-04-23 2009-10-29 Isis Innovation Limited Virus
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
WO2011028550A1 (en) * 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Segmented micro rna mimetics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US8258256B2 (en) 2006-01-05 2012-09-04 The Johns Hopkins University Compositions and methods for the treatment of cancer
WO2007094653A1 (en) 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122385A1 (en) * 2004-04-15 2007-05-31 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Replication competent viruses capable of silencing virus inhibitory factor expression
WO2009130479A2 (en) * 2008-04-23 2009-10-29 Isis Innovation Limited Virus
WO2010138263A2 (en) * 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
WO2011028550A1 (en) * 2009-08-24 2011-03-10 Merck Sharp & Dohme Corp. Segmented micro rna mimetics

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
CAWOOD RYAN ET AL: "Use of tissue-specific microRNA to control pathology of wild-type adenovirus without attenuation of its ability to kill cancer cells", PLOS PATHOGENS, vol. 5, no. 5, E1000440, 1 May 2009 (2009-05-01), PUBLIC LIBRARY OF SCIENCE, SAN FRANCISCO, CA, US, pages 1 - 10, XP002544786, ISSN: 1553-7366, DOI: 10.1371/JOURNAL.PPAT.1000440 *
DATABASE Geneseq [online] 31 March 2011 (2011-03-31), "Human microRNA (miRNA) sequence SEQ ID NO:309.", XP002665897, retrieved from EBI accession no. GSN:AZF38975 Database accession no. AZF38975 *
E. YLÖSMÄKI ET AL: "Generation of a Conditionally Replicating Adenovirus Based on Targeted Destruction of E1A mRNA by a Cell Type-Specific MicroRNA", JOURNAL OF VIROLOGY, vol. 82, no. 22, 15 November 2008 (2008-11-15), pages 11009 - 11015, XP055006997, ISSN: 0022-538X, DOI: 10.1128/JVI.01608-08 *
ELIZABETH J KELLY ET AL: "MicroRNAs and the Regulation of Vector Tropism", MOLECULAR THERAPY, vol. 17, no. 3, 1 March 2009 (2009-03-01), pages 409 - 416, XP055007015, ISSN: 1525-0016, DOI: 10.1038/mt.2008.288 *
GÜRLEVIK ENGIN ET AL: "p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication.", NUCLEIC ACIDS RESEARCH, vol. 37, no. 12, E84, July 2009 (2009-07-01), pages 1 - 12, XP002658934, ISSN: 1362-4962 *
JUSTYNA LEJA ET AL: "Double-Detargeted Oncolytic Adenovirus Shows Replication Arrest in Liver Cells and Retains Neuroendocrine Cell Killing Ability", PLOS ONE, vol. 5, no. 1, E8916, 1 January 2010 (2010-01-01), pages 1 - 9, XP055006991, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0008916 *
KELLY ELIZABETH J ET AL: "Engineering microRNA responsiveness to decrease virus pathogenicity", NATURE MEDICINE, vol. 14, no. 11, 1 November 2008 (2008-11-01), NATURE PUBLISHING GROUP, NEW YORK, NY, US, pages 1278 - 1283, XP002544787, ISSN: 1078-8956, [retrieved on 20081026], DOI: 10.1038/NM.1776 *
LEINA MA ET AL: "Expression of miR-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cancer cells.", CANCER BIOLOGY & THERAPY, vol. 9, no. 7, 1 April 2010 (2010-04-01), pages 554 - 561, XP055007035, ISSN: 1538-4047, DOI: 10.4161/cbt.9.7.11267 *
ROBERT E EDGE ET AL: "A let-7 MicroRNA-sensitive Vesicular Stomatitis Virus Demonstrates Tumor-specific Replication", MOLECULAR THERAPY, vol. 16, no. 8, 1 August 2008 (2008-08-01), pages 1437 - 1443, XP055007006, ISSN: 1525-0016, DOI: 10.1038/mt.2008.130 *
TAKAYUKI SUZUKI ET AL: "miR-122a-Regulated Expression of a Suicide Gene Prevents Hepatotoxicity Without Altering Antitumor Effects in Suicide Gene Therapy", MOLECULAR THERAPY, vol. 16, no. 10, 29 July 2008 (2008-07-29), pages 1719 - 1726, XP055006986, ISSN: 1525-0016, DOI: 10.1038/mt.2008.159 *
TONG ALEX W: "SMALL RNAS AND NON-SMALL CELL LUNG CANCER", CURRENT MOLECULAR MEDICINE, vol. 6, no. 3, 1 May 2006 (2006-05-01), BENTHAM SCIENCE PUBLISHERS, NL, pages 339 - 349, XP008070735, ISSN: 1566-5240, DOI: 10.2174/156652406776894554 *

Also Published As

Publication number Publication date
WO2012047109A2 (en) 2012-04-12

Similar Documents

Publication Publication Date Title
IL264441A (en) Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors
WO2012062810A3 (en) Cell culture medium and process for protein expression, said medium and process comprising a pam inhibitor
WO2012142498A3 (en) Mif inhibitors and their uses
WO2013096709A3 (en) Methods of increasing the viability or longevity of an organ or organ explant
WO2010033225A3 (en) Compositions and methods for the specific inhibition of gene expression by dsrna
BRPI0906237A2 (en) manipulation of cell information system and specific time for delivery in another evolved.
WO2012092515A9 (en) Methods, systems, and computer readable media for nucleic acid sequencing
TR201910686T4 (en) Lipid nanoparticle compositions and methods for Mrna delivery.
WO2012064806A3 (en) Methods and compositions for unsilencing imprinted genes
WO2013109856A3 (en) Methods of using fgf19 modulators
WO2013023084A3 (en) Methods and compositions for inhibiting the growth and/or proliferation of myc-driven tumor cells
PL2673345T3 (en) Use of liquid compositions for marking liquid hydrocarbon-based fuels and combustibles, and process for detecting the markers
EP2814976A4 (en) Methods and kits for reducing non-specific nucleic acid amplification
EP2795839A4 (en) System and method for measuring and improving the efficiency of social media campaigns
WO2012102527A3 (en) Novel use of regulatory t cell-specific surface protein lrig-1
WO2012145729A3 (en) Methods and compositions for modulating gene expression using components that self assemble in cells and produce rnai activity
WO2012174378A3 (en) Methods and materials for assessing allelic imbalance
IN2015KN00073A (en)
MX349801B (en) Nucleic acid enzyme substrates.
WO2012027713A3 (en) Compositions and methods for inhibition of snca
EA033514B1 (en) Methods and compositions for analyzing ahasl genes in wheat
MX2013005244A (en) Low-extractable thioxanthones.
WO2012030854A3 (en) Compositions and methods for modulating emt and uses thereof
MX2014006088A (en) Biomarkers for cancers responsive to modulators of hec1 activity.
WO2012047109A3 (en) Mirna and mirna inhibitors that modulate adenovirus replication and/or adenovirus induced cell death

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11770560

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11770560

Country of ref document: EP

Kind code of ref document: A2